AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00506155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 30 mg/m\^2 by vein over 30 minutes
Study NCT00506155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: 3 mg/m\^2 by vein over 30 minutes
Study NCT03072134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neural stem cells loaded with an oncolytic adenovirus
Description: The primary objectives are to evaluate the safety of the combined therapy and determine the maximum tolerated dose (MTD) for a future Phase II study.
Study NCT01018199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRP
Description: C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy
Study NCT01018199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PCT
Description: Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy
Study NCT04174911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-DP-o-08
Description: BOL-DP-o-08 sublingual drops
Study NCT04174911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sublingual drops
Study NCT00670852 — intervention group
Intervention type: PROCEDURE
Intervention: X-rays and CT scan
Description: CT Scan x-rays
Study NCT02049333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification
Study NCT02049333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Study NCT02899533 — intervention group
Intervention type: DRUG
Intervention: [18F] FES
Description: \[18F\] FES PET/CT scan, imaging tracer
Study NCT02556697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with in vivo confocal endomicroscopy
Description: A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma
Study NCT01359059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
Study NCT05466760 — intervention group
Intervention type: RADIATION
Intervention: PET/MR
Description: Study 1- pre-NAC PET/MR; Study 2- first follow-up PET/MR is performed after first dose of NAC; Study 3, second follow-up PET/MR is performed after third or fourth dose of the NAC. The NAC protocol is mainly antracycline-based followed by taxane-based regimen for a total of 6-8 cycles.
Study NCT02084576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac
Description: One drop in the study eye 3 times daily for 30 days
Study NCT02049333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Cycloplasty (ECPL)
Study NCT02084576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: One drop in the study eye 4 times daily for 30 days
Study NCT02339194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Denture fabrication technique
Description: Both arm groups are composed by patients present severely resorbed mandibular alveolar bones who will receive complete dentures fabricated by means of a simpler techinique previously proved to be effective. Although for the traditional protocol group a second more complex impression step will be performed in order to evaluate if the simpler approach for this anatomical condition could be safely applied.
Study NCT01255995 — intervention group
Intervention type: DEVICE
Intervention: Capsular Tension Ring
Description: Capsular Tension Ring
Study NCT03088943 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TTE Apical 4 Chamber View
Description: We will measure a number of echocardiography parameters by TTE (apical 4 Chamber View) prior to and after induction
Study NCT03088943 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TEE dTG View
Description: We will measure a number of echocardiography parameters by TEE (dTG View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
Study NCT04645303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid (20 mg/2 mL)
Description: A1-Pulley infiltration for trigger finger
Study NCT03088943 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TEE ME 4C View
Description: We will measure a number of echocardiography parameters by TEE (ME 4C View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
Study NCT00449644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.
Study NCT00449644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.
Study NCT01982461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10mg,once daily
Study NCT01982461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor®
Description: 10mg,once daily
Study NCT03858530 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Examination
Description: Grayscale ultrasound, Doppler ultrasound, ultrasound elastography with or without ultrasound intravenous contrast will be performed.
Study NCT00449644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)
Description: Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
Study NCT00449644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)
Description: Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
Study NCT01660854 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heterologous challenge
Description: challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
Study NCT01948063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubiquinol
Description: Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
Study NCT01948063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
Study NCT03415438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Analogue Scale
Description: intensity of pain perception patients feel
Study NCT03415438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: posterior capsule tightness
Description: tape measurement for posterior capsule tightness with patients lying at side and horizontally adducting their shoulder.
Study NCT03415438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: shortness tests for lumbar movements
Description: tape measurement for lumbar movements
Study NCT03415438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: range of motion tests for lumbar movements
Description: range of motion measurements for lumbar flexion, extension and lateral flexion with goniometer.
Study NCT03415438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The thoracolumbar fascia length test
Description: patient sitting straight with shoulders at horizontal plane, both the arms are asked to rotated with primarily spinal rotation. the degree of rotation gives idea about the thoracolumbar fascia length
Study NCT03415438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Modify Schober test
Description: tape measurement of spinal flexion between designated regions
Study NCT00887510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: 25 mg tablet once daily for 6 weeks~Other Names:~HCTZ
Study NCT00887510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trandolapril
Description: 4 mg tablet once daily for 6 weeks
Study NCT03466736 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]flutemetamol PET scan
Description: Each subject will receive an amyloid PET scan with \[18F\]flutemetamol
Study NCT01660854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heterologous challenge
Description: challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
Study NCT01660854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malarone treatment
Description: Three days: 4 tablets 250/100mg per day
Study NCT01660854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malarone treatment
Description: Three days: 4 tablets 250/100mg per day
Study NCT01136096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity promoting intervention
Description: 1. An interview with a physiotherapist~2. An exercise video specially designed by this study including warm-up, aerobic, cool-down and stretching exercises, and/or a simple exerciser to use at home~3. An individualized home-based exercise program based on the Health Belief Model and Transtheoretical Model~4. The daily record to check their body weight, exercise mode and duration~5. Proper diet, caloric intake calculation, metabolic risk factors and prevention of diabetes were taught and a guide book was provided that included all the above mentioned details~6. Telephone reminders of healthy lifestyle including the ways of overcoming barriers of regular exercise every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule
Study NCT01136096 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: General instruction and education
Description: 1. Oral instruction and written general education information about weight control, proper diet and regular exercise in a one-page education brochure that was similar to the way used in the outpatient clinic~2. Telephone reminders of healthy lifestyle every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule~3. Without individualized exercise program and interview with a physiotherapist
Study NCT01296295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling and spirometry
Description: The patients of the intervention group will be given a brief structured smoking cessation advice by their primary care physician combined with a detailed and structured discussion of the spirometry results.
Study NCT06584370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericardial insufflation with carbon dioxide through a transatrial microcatheter
Description: Separate the walls of the pericardium by insufflating the pericardial space with carbon dioide.
Study NCT00859937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT00859937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03817112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride 0.1 MG/ML
Description: Dexmedetomidine Hydrochloride 0.1 MG/ML infusion at 0.2-0.7 mcg/kg/min
Study NCT03817112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 10 MG/ML
Description: Propofol 10 MG/ML infusion at 0.3 -4 mg/kg/h
Study NCT03060954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINI WELL READY ®
Description: BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
Study NCT03060954 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FINE VISION®
Description: FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
Study NCT00006249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa
Study NCT00006249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT01296295 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Smoking cessation advice
Description: Brief smoking cessation advice
Study NCT04222712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRS01 eye drops
Description: Dosed four times a day (QID)
Study NCT03530579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational group trainings
Description: Participants will receive 6 two and a half hour educational group training's over the course of 6 months. These sessions will be led by a trained CHW in your language and will be held on a monthly basis in a community based location.~Session 1: What is Diabetes~* Why is Prevention Important~Session 2: Nutrition Session 3: Physical Activity Session 4: Cardiovascular Disease \& Diabetes Complication Session 5: Stress Management Session 6: Access to Service
Study NCT03530579 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Care Worker
Description: A community health care worker answer your questions about diabetes and refer participant to a physician. Survey will be completed at the start of the study and during the 3rd, 6th and 12th months
Study NCT00864747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride Extended Release Capsules 160 mg
Description: A: Experimental Subjects received Actavis formulated products under non-fasting conditions
Study NCT01329939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Age-dependent dose, nightly, 24 weeks
Study NCT01329939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Age-dependent dose, nightly, 24 weeks
Study NCT01329939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Age-dependent dose, nightly, 24 weeks
Study NCT01383317 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thigh Tourniquet (VBM Single Use Tourniquet Cuff Items 20-34-722SLZ-1)
Description: Disposable sterile thigh tourniquet
Study NCT00033553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Arm A: AUC=6 IV over 30 min for 2 cycles then AUC=2 IV over 30 min q wk for 7 wks Arm B: AUC=5 IV over 30 min for 2 cycles
Study NCT00033553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/sq m IV over 30 min days 1 \& 8 repeat q 21 days for 2 cycles; then 35 mg/sq m IV over 30 min 2X wk for 7 wks
Study NCT00033553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 225 mg/sq m IV over 3 hrs q 21 days for 2 cycles, then 45 mg/sq m IV over 1 hr q wk for 7 wks
Study NCT00033553 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 3-D XRT 7400 cGy total after induction (during cycles 3-9)
Study NCT03364738 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: Participants will receive rhPTH(1-84) SC injection in the thigh (alternate thigh every day) QD.
Study NCT01383317 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham RIPC
Description: Disposable sterile thigh tourniquet
Study NCT03730987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HoMBReS intervention
Description: Adapted intervention based on social cognitive theory and empowerment education that aims to reduce risky sexual behaviors, substance abuse and HIV among recently immigrated rural and urban men.
Study NCT03560167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCinch® Ventricular Restoration System
Description: AccuCinch® Ventricular Restoration System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
Study NCT03330795 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3/CD19 neg allogeneic BMT
Description: Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
Study NCT03245398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with one of the two regimens of mebendazole
Description: Once in the morning and once in the evening for 3 consecutive days
Study NCT00989963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium Modified Release
Description: 60µg Tablets, twice a day for 12 weeks
Study NCT00964821 — intervention group
Intervention type: BIOLOGICAL
Intervention: trivalent influenza vaccine
Description: Patients or normal volunteers who will be vaccinated against the flu.
Study NCT00964821 — intervention group
Intervention type: OTHER
Intervention: Immunoenzyme technique
Description: This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
Study NCT00964821 — intervention group
Intervention type: OTHER
Intervention: Laboratory biomarker analysis
Description: This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
Study NCT00880191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT00880191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: Given orally
Study NCT00880191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study NCT01677858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day treatment cycle.
Study NCT01677858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone was administered at a dose of 40 mg IV or orally (PO) on days 1, 8, 15, and 22 for the first 8 cycles; starting with cycle 9 dexamethasone was administered on days 1, 8, and 15.
Study NCT00864747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INDERAL® LA 160 mg Capsules, single dose
Description: B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
Study NCT01024907 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam radiation therapy
Description: Undergo radiation
Study NCT01024907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary study
Study NCT03730987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Talking Together (FTT)
Description: The brief intervention, is a parent-based intervention to teach parents effective strategies proven to reduce adolescent sexual risk behavior. The intervention specifically targets the parent (not the adolescent) to: promote communication skills, build parent-adolescent relationships, develop effective monitoring strategies, reduce alcohol use, risky sexual behaviors and prepare them to teach adolescents assertiveness and substance abuse refusal skills.
Study NCT01024907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary study
Study NCT01972737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-hGCC-PADRE vaccine
Description: A single intramuscular dose (100 billion virus particles) of Ad5-hGCC-PADRE vaccine.
Study NCT04130399 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Patients will receive 5 fractions of SBRT delivered over a five-day period. Treatment may be delivered over 2 weeks, provided that the patient receives at least 2 fractions per week.
Study NCT04130399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines
Study NCT00483964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacopa monnieri
Study NCT00483964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nardostachys jatamansi
Study NCT00483964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine